Filtreler
Recent updates on true potential of an anesthetic agent as a regulator of cell signaling pathways and non-coding RNAs in different cancers: Focusing on the brighter side of propofol

Farooqi, A.A. | Adylova, A. | Sabitaliyevich, U.Y. | Attar, Rukset | Sohail, M.I. | Yilmaz, S.

Review | 2020 | Gene737

There has always been a quest to search for synthetic and natural compounds having premium pharmacological properties and minimum off-target and/or side effects. Therefore, in accordance with this approach, scientists have given special attention to the molecules having remarkable ability to target oncogenic protein network, restore drug sensitivity and induce apoptosis in cancer cells. The mechanisms through which general anesthetics modulated wide-ranging deregulated cell signaling pathways and non-coding RNAs remained unclear. However, rapidly accumulating experimentally verified evidence has started to resolve this long-standing . . . mystery and a knowledge about these important molecular targets has surfaced and how these drugs act at the molecular level is becoming more understandable. In this review we have given special attention to available evidence related to ability of propofol to modulate Wnt/ß-catenin, JAK/STAT and mTOR-driven pathway. Excitingly, great strides have been made in sharpening our concepts related to potential of propofol to modulate non-coding RNAs in different cancers. Collectively, these latest findings offer interesting, unexplored opportunities to target deregulated signaling pathways to induce apoptosis in drug-resistant cancers. © 2020 Elsevier B.V Daha fazlası Daha az

Tudor tells about new twists in the story tale of SMURFs

Qureshi, M.Z. | Jabeen, S. | Butt, G. | Aslam, A. | Naqvi, S.K.-U.-H. | Attar, Rukset | Farooqi, A.A.

Review | 2016 | Cellular and Molecular Biology62 ( 5 ) , pp.38 - 43

Smad ubiquitin regulatory factors (SMURFS) belong to the HECT- family of E3 ubiquitin ligases. This family has two members, SMURF1 and SMURF2. SMURFs have emerged as well studied negative regulators of TGF induced intracellular signaling. However, increasingly it is being realized that SMURFs tactfully modulate an array of proteins in different cancers. This review sets spotlight on how SMURF1 and SMURF2 communicate with effectors of different signaling pathways during the multistep progression to cancer. We also summarize how microRNAs (miRNAs) effectively control SMURFs in different cancers. Role of SMURFs is context dependent in . . .different cancers and better concepts related to miRNA regulation of SMURFs in different stages and steps of cancer will be helpful in efficient translation of laboratory findings to clinic. © 2016 by the C.M.B. Association. All rights reserved Daha fazlası Daha az

From endometriosis to cancer: Spotlight on intracellular signaling cascades and Micro RNAs

Halim, T.A. | Attar, Rukset | Donfrancesco, C. | Farooqi, A.A. | Zaman, F.

Book Part | 2018 | Recent Trends in Cancer Biology: Spotlight on Signaling Cascades and MicroRNAs: Cell Signaling Pathways and MicroRNAs in Cancer Biology , pp.1 - 10

Increasingly sophisticated information has started to shed light on essential role of signal transduction cascades in endometriosis and how these pathways promote transformations from benign to premalignant endometriosis. It is becoming progressively more understandable that genetic/epigenetic mutations, inactivation of tumor suppressors, aberrant expression of different microRNAs play decisive role in malignant transformation of endometriosis. © Springer International Publishing AG 2018.

Regulation of signaling pathways by Ampelopsin (Dihydromyricetin) in different cancers: exploring the highways and byways less travelled

Fayyaz, S. | Qureshi, M.Z. | Alhewairini, S.S. | Avnioglu, S. | Attar, Rukset | Sabitaliyevich, U.Y. | Pawlak-Adamska, E.

Article | 2019 | Cellular and molecular biology (Noisy-le-Grand, France)65 ( 7 ) , pp.15 - 20

Ampelopsin or Dihydromyricetin is gradually emerging as a high-quality natural product because of its ability to modulate wide-ranging signaling pathways. Ampelopsin (Dihydromyricetin) has been reported to effectively modulate growth factor receptor (VEGFR2 and PDGFRß) mediated signaling,  TRAIL/TRAIL-R pathway, JAK/STAT and mTOR-driven signaling in different cancers. Ampelopsin (Dihydromyricetin) has also been shown to exert inhibitory effects on the versatile regulators which trigger EMT (Epithelial-to-Mesenchymal Transition). Findings obtained from in-vitro studies are encouraging and there is a need to comprehensively analyze ho . . .w Ampelopsin (Dihydromyricetin) inhibits tumor growth in different cancer models. Better knowledge of efficacy of Ampelopsin (Dihydromyricetin) in tumor bearing mice will be helpful in maximizing its translational potential Daha fazlası Daha az

6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms